Chembio
Supports CDC’s
Timely Recommendation For
Routine
HIV Testing as the US Conference on AIDS Begins
Chembio
to Participate in Conference and Showcase
SURE
CHECK(R) HIV 1/2 and HIV 1/2 STAT-PAK(TM)
N.Y.
-
September 21, 2006 - Chembio Diagnostics, Inc. (OTCBB:CEMI) strongly
supports
the U.S.
Centers for Disease Control and Prevention’s (CDC) HIV testing final
recommendations issued this morning that all Americans between the ages
of 13 to
64 be tested for HIV as a part of routine medical care. Today’s news comes just
as the US Conference on AIDS begins in Hollywood, Florida. At the conference,
which runs from September 21-25, Chembio will exhibit its two FDA-approved
rapid
HIV tests, SURE
CHECK(R) HIV 1/2 and HIV 1/2 STAT-PAK(TM), at booth #803.
Lawrence
Siebert, President and CEO of Chembio,
commented, “We are pleased the CDC now officially recommends routine HIV
testing. Routine
testing is
essential in the battle against HIV infection and AIDS, in America and
globally.
We believe our SURE CHECK(R) HIV 1/2 and HIV 1/2 STAT-PAK(TM) tests will
play an
important role in helping to identify and control the disease.”
Chembio
anticipates signing a US marketing agreement while its CLIA (Clinical Laboratory
Improvement Act) waiver applications are being reviewed. A CLIA waiver,
if
granted, would greatly expand the available market for SURE CHECK and STAT
PAK
from hospitals and certified laboratories to also include public health
clinics,
doctors’ offices and other settings. The Company believes that the guidelines
for routine HIV testing that were released by the CDC will be implemented
in
these settings in the near future.
ABOUT
CHEMBIO
Chembio
Diagnostics, Inc., a developer and manufacturer of rapid diagnostic tests
for
infectious diseases, is on the frontlines of the global battle against
the AIDS
pandemic. The Company has received marketing approval from the FDA for
its SURE
CHECK(R) HIV 1/2 and HIV 1/2 STAT-PAK(TM) rapid tests. The Company also
manufactures rapid tests for veterinary Tuberculosis and Chagas Disease,
and has
developed a patent-pending technology, the Dual Path Platform (DPP(TM)),
for its
next generation HIV and other rapid tests. For additional information please
visit www.chembio.com.
FORWARD-LOOKING
STATEMENTS
Statements
contained herein that are not historical facts may be forward-looking statements
within the meaning of the Securities Act of 1933, as amended. Forward-looking
statements include statements regarding the intent, belief or current
expectations of the Company and its management. Such statements are estimates
only, as the Company has not completed the preparation of its financial
statements for those periods, nor has its auditor completed the audit of
those
results. Actual revenue may differ materially from those anticipated in
this
press release. Such statements reflect management's current views, are
based on
certain assumptions and involve risks and uncertainties. Actual results,
events,
or performance may differ materially from the above forward-looking statements
due to a number of important factors, and will be dependent upon a variety
of
factors, including, but not limited to Chembio's ability to obtain additional
financing, to obtain regulatory approvals in a timely manner, and the demand
for
Chembio's products. Chembio undertakes no obligation to publicly update
these
forward-looking statements to reflect events or circumstances that occur
after
the date hereof or to reflect any change in Chembio's expectations with
regard
to these forward-looking statements or the occurrence of unanticipated
events.
Factors that may impact Chembio's success are more fully disclosed in Chembio's
most recent public filings with the U.S. Securities and Exchange
Commission.
Contact:
The
Investor Relations Group 212-825-3210
Investors:
James Carbonara
Media:
Susan Morgenbesser